CORDIS
EU research results

CORDIS

English EN

THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia

Objective

THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia.
THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management.
The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments.
Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI FERRARA

Address

Via Ariosto 35
44121 Ferrara

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 584 000

Administrative Contact

Roberto Gambari (Prof.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CYPRUS FOUNDATION FOR MUSCULAR DYSTROPHY RESEARCH

Cyprus

EU Contribution

€ 440 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 370 000

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 370 000

CORNELL UNIVERSITY

United States

EU Contribution

€ 233 587,33

Masarykova univerzita

Czechia

EU Contribution

€ 320 000

UNIVERSITA DEGLI STUDI DI CAGLIARI

Italy

EU Contribution

€ 320 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 320 000

GENIKO LAIKO NOSOKOMEIO ATHINON*GENERAL HOSPITAL OF ATHENS LAIKO

Greece

EU Contribution

€ 320 000

NOVAMECHANICS LIMITED

Cyprus

EU Contribution

€ 620 477,53

BIOCEPS

Israel

EU Contribution

€ 97 761

HARBOUR ANTIBODIES BV

Netherlands

EU Contribution

€ 100 000

IRBM SCIENCE PARK SPA

Italy

EU Contribution

€ 787 761,47

THE CHILDREN'S HOSPITAL OF PHILADELPHIA NON PROFIT ORG

United States

EU Contribution

€ 136 412,67

Project information

Grant agreement ID: 306201

Status

Closed project

  • Start date

    1 November 2012

  • End date

    30 April 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 6 730 513,08

  • EU contribution

    € 5 020 000

Coordinated by:

UNIVERSITA DEGLI STUDI DI FERRARA

Italy

This project is featured in...